DUSP22 and anaplastic large cell lymphoma: The clinical impact of DUSP22 rearrangement remains controversial: the initially reported markedly superior prognosis of these cases was not confirmed in subsequent studies, while data from more recent cohorts still support an intermediate prognosis of DUSP22-rearranged ALK− ALCL, standing between ALK+ ALCL and DUSP22-non rearranged ALK− ALCL [23, 24].